Zevra Therapeutics (NASDAQ:ZVRA) shares are up on Tuesday following a new partnership with GeneDx Holdings Corp. (NASDAQ:WGS) to enhance genetic testing for Niemann-Pick Disease type C, or NPC.
Niemann-Pick disease type C (NPC) is a rare, inherited, and progressive neurovisceral disorder caused by mutations in the NPC1 or NPC2 genes, leading to the accumulation of cholesterol and lipids in cells.
It causes severe, progressive neurological decline, including dementia, ataxia, and vertical supranuclear gaze palsy, often resulting in premature death. There is no cure, so care focuses on managing symptoms
This collaboration aims to improve diagnosis and treatment options for patients.
GeneDx announced a genetic testing program with Zevra Therapeutics, designed to expand access to its ExomeDx test for suspected NPC cases.
“Through our partnership with Zevra we are removing barriers to high-quality exome sequencing so clinicians can reach answers faster, confirm diagnoses with precision, and identify patients earlier,” said Lisa Gurry, chief business officer at GeneDx.
“Our partnership programs are fueled by the GeneDx Infinity dataset – the world’s largest rare-disease genomic dataset – enabling biopharma partners to better understand disease biology, and accelerate the patient journey from diagnosis to treatment. This is how we translate genomic insight into transformative, real-world impact for patients,” Gurry added.
Zevra Therapeutics reported fourth-quarter results on Monday.
Fourth-Quarter Results
The latest development follows the company’s fourth-quarter results reported on March 9. Zevra Therapeutics reported fourth-quarter earnings of 19 cents a share, beating analyst estimates of 5 cents.
Sales totaled $34.1 million, topping estimates of $28.1 million. As of December 31, 2025, the firm had cash and equivalents worth $62.406 million.
“MIPLYFFA is making a meaningful difference for patients with Niemann-Pick disease type C, and its strong, accelerating performance reinforces our confidence in its long-term potential,” said Neil F. McFarlane, Zevra’s President and Chief Executive Officer. “We have officially relocated our global corporate headquarters to Boston, enhancing our access to a deep and highly specialized talent pool.”
“Looking ahead, we are focused on executing against multiple near-term growth opportunities in 2026, and believe we are well-positioned to execute on our strategic priorities to create meaningful value for the rare disease community and our shareholders,” McFarlane added.
ZVRA Price Action: Zevra Therapeutics shares were up 21.71% at $10.93 at the time of publication on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments